IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)

2. (Currently amended) A method for evaluating the effectiveness of an HIV reverse transcriptase inhibitor <u>excluding AZT</u> as an anti HIV therapy for a patient infected with at least one mutant HIV strain comprising:

    (i)   collecting a sample from an HIV-infected patient;

(ii)   determining whether the sample comprises a nucleic acid encoding HIV reverse transcriptase having at least one mutation at the position 194, wherein the wild type amino acid is mutated to glycine <u>as compared to the wild-type HIV strain IIIB/LAI</u>;

~~(iii) correlating the presence of said at least one mutation of step (ii) to a change in effectiveness of said HIV reverse transcriptase inhibitor;~~

~~(iv)~~ <u>(iii)</u> ~~determining~~<u>introducing</u> ~~the effectiveness of~~ said HIV reverse transcriptase inhibitor <u>to said sample containing said mutation</u>; ~~and~~

~~(v)~~ <u>(iv)</u> comparing the effectiveness of said inhibitor in <u>said</u> samples containing said reverse transcriptase mutation, with <u>a</u> sample~~s not~~ containing <u>no</u> said mutation~~-~~<u>; and</u>

<u>(v)   correlating the presence of said at least one mutation of step (ii) to a change in effectiveness of said HIV reverse transcriptase inhibitor.</u>

3. to 4. (Canceled)

5. (Currently amended) A method for evaluating a change in ~~anti HIV drug~~ susceptibility <u>of an HIV reverse transcriptase inhibitor</u> <u>excluding AZT</u> comprising:

    (i)   collecting a sample from an HIV-infected patient;

(ii)   determining whether the sample comprises an HIV reverse transcriptase having at
        least one mutation at the position 194, wherein the wild type amino acid is
        mutated to glycine <u>as compared to the wild-type HIV strain IIIB/LAI</u>;

~~(iii)   correlating the presence of said at least one mutation of step (ii) to a change in anti
        HIV drug susceptibility;~~

~~(iv)~~ <u>(iii)</u> ~~determining~~<u>introducing</u> ~~the effectiveness of a~~ <u>said</u> reverse transcriptase inhibitor
        <u>to said sample containing said mutation</u>; ~~and~~

~~(v)~~ <u>(iv)</u> comparing the anti HIV drug effectiveness in <u>said</u> ~~samples~~ containing said reverse
transcriptase mutation with <u>a</u> samples not containing said mutation~~.~~<u>; and</u>

<u>(v)   correlating the presence of said at least one mutation of step (ii) to a change in
susceptibility of said HIV reverse transcriptase inhibitor.</u>